Name: Folinic acid calcium salt pentahydrate | Leucovorin Calcium Pentahydrate; Leucovorin calcium salt pentahydrate
Brand: Ambeed
SKU: A246079
Rating: 4.4 (102 reviews)

CAS No. :	6035-45-6
Formula :	C₂₀H₃₁CaN₇O₁₂
M.W :	601.58
SMILES Code :	O=CN1C(C2=O)=C(NC(N)=N2)NCC1CNC3=CC=C(C(N[C@H](C([O-])=O)CCC([O-])=O)=O)C=C3.O.O.O.O.[Ca+2].O
Synonyms :	Leucovorin Calcium Pentahydrate; Leucovorin calcium salt pentahydrate
MDL No. :	MFCD00149465
InChI Key :	NPPBLUASYYNAIG-ZIGBGYJWSA-L
Pubchem ID :	135802074

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H317-H319-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Human aortic endothelial cells (HAEC)	10 μM	1 hour	To evaluate the effect of BH4 treatment on intracellular BH4 and 7,8-BH2 levels. Results showed a transient increase in intracellular BH4 followed by accumulation of 7,8-BH2.	Free Radic Biol Med. 2013 Oct;63:143-50.
Human umbilical vein endothelial cells (HUVEC)	500 nM	24 h	Folinic acid reversed MTX-induced p38 MAPK and Akt phosphorylation and reduced MTX-induced pro-inflammatory cell adhesion molecules (VCAM1, ICAM1, and E-selectin) expression.	Front Immunol. 2023 Jun 30;14:1209490.
MCA38 colorectal cancer cell line	10 μM	48 h	To evaluate the effect of FOLFOX (including folinic acid) on MCA38 cells, confirming cell death and activation of inflammatory signaling.	Br J Cancer. 2013 Oct 29;109(9):2396-403.

BALB/c mice	Acute Toxoplasma gondii RH strain infection model	Oral administration	15 mg/kg	Once daily for 7 consecutive days	As a positive control drug to evaluate the therapeutic effect of folinic acid on acute Toxoplasma gondii infection	Parasit Vectors. 2024 Mar 1;17(1):96
BALB/c mice	Acute Toxoplasma gondii infection model	Oral administration	15 mg/kg	Once daily for 15 consecutive days	Evaluated the therapeutic effect of folinic acid on acute infection, results showed all mice in the positive control drug groups survived	Front Cell Dev Biol. 2021 Jun 11;9:684393
BALB/c mice	Toxoplasma gondii infection model	Oral	15 mg/kg	Once a day for 30 days	Evaluate the safety of folinic acid in Toxoplasma gondii infection model	Front Microbiol. 2019 Sep 18;10:2152
BALB/c mice	Acute T. gondii infection model	Oral administration	15 mg/kg	Once daily for 7 consecutive days	To evaluate the therapeutic effect of folinic acid on acute T. gondii infection, all mice in the positive drug groups survived.	Int J Parasitol Drugs Drug Resist. 2019 Apr;9:27-34
C57Bl/6 mice	Colorectal liver metastases (CRLM) model	Intraperitoneal (i.p.)	90 mg kg	Weekly cycles, terminated one day after the third treatment	To evaluate the effect of FOLFOX (including folinic acid) on the CRLM model, finding that tumour-related factors exacerbated FOLFOX-induced liver injury.	Br J Cancer. 2013 Oct 29;109(9):2396-403.

NCT00720109	Adult B Acute Lymphoblastic Le... More >>ukemia With t(9;22)(q34;q11.2); BCR-ABL1 Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Less <<	Phase 2 Phase 3	Completed	-	-
NCT01256398	Acute Lymphoblastic Leukemia ... More >> Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Untreated Adult Acute Lymphoblastic Leukemia Less <<	Phase 2	Active, not recruiting	-	-
NCT00720109	-		Completed	-	-
NCT00792948	-		Active, not recruiting	-	-
NCT02101853	B Acute Lymphoblastic Leukemia	Phase 3	Recruiting	-	-
NCT00792948	Acute Lymphoblastic Leukemia ... More >> Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Adult L1 Acute Lymphoblastic Leukemia Adult L2 Acute Lymphoblastic Leukemia Adult T Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Less <<	Phase 2	Active, not recruiting	September 24, 2019	-
NCT02112916	Adult T Acute Lymphoblastic Le... More >>ukemia Ann Arbor Stage II Adult Lymphoblastic Lymphoma Ann Arbor Stage II Childhood Lymphoblastic Lymphoma Ann Arbor Stage III Adult Lymphoblastic Lymphoma Ann Arbor Stage III Childhood Lymphoblastic Lymphoma Ann Arbor Stage IV Adult Lymphoblastic Lymphoma Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma Childhood T Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Less <<	Phase 3	Suspended(Other - Temporary cl... More >>osure) Less <<	-	-
NCT01190930	Acute Lymphoblastic Leukemia ... More >> Adult B Lymphoblastic Lymphoma Ann Arbor Stage I B Lymphoblastic Lymphoma Ann Arbor Stage II B Lymphoblastic Lymphoma Childhood B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Childhood B Lymphoblastic Lymphoma Down Syndrome Hypodiploid B Acute Lymphoblastic Leukemia Intrachromosomal Amplification of Chromosome 21 Philadelphia Chromosome Positive Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Less <<	Phase 3	Active, not recruiting	-	-
NCT02883049	B Acute Lymphoblastic Leukemia... More >> Central Nervous System Leukemia Ph-Like Acute Lymphoblastic Leukemia Testicular Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Less <<	Phase 3	Recruiting	-	-
NCT02730546	Gastric Cardia Adenocarcinoma ... More >> Gastroesophageal Junction Adenocarcinoma Stage IB Gastric Cancer AJCC v7 Stage II Gastric Cancer AJCC v7 Stage IIA Gastric Cancer AJCC v7 Stage IIB Gastric Cancer AJCC v7 Stage IIIA Gastric Cancer AJCC v7 Stage IIIB Gastric Cancer AJCC v7 Less <<	Phase 1 Phase 2	Recruiting	April 15, 2021	United States, Arizona ... More >> Mayo Clinic Hospital Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Referral Office 866-776-0015 Principal Investigator: Daniel H. Ahn United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Harry H. Yoon Less <<
NCT00321685	Rectal Adenocarcinoma ... More >> Stage II Rectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7 Less <<	Phase 2	Active, not recruiting	May 1, 2020	-
NCT00321685	-		Active, not recruiting	-	-
NCT02779283	Acute Lymphoblastic Leukemia ... More >> Acute Myeloid Leukemia Less <<	Phase 1	Recruiting	June 1, 2019	United States, Oregon ... More >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Stephen E. Spurgeon 503-494-8950 spurgeos@ohsu.edu Principal Investigator: Stephen E. Spurgeon Less <<
NCT03007147	B Acute Lymphoblastic Leukemia... More >> BCR-ABL1 Fusion Protein Expression Minimal Residual Disease Philadelphia Chromosome Positive T Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia Less <<	Phase 3	Recruiting	June 30, 2026	-
NCT02921256	Rectal Adenocarcinoma ... More >> Stage II Rectal Cancer AJCC v7 Stage III Rectal Cancer AJCC v7 Less <<	Phase 2	Recruiting	-	-
NCT02828358	Acute Leukemia of Ambiguous Li... More >>neage Childhood B Acute Lymphoblastic Leukemia KMT2A Gene Rearrangement Mixed Phenotype Acute Leukemia Less <<	Phase 2	Suspended(Met accural pending ... More >>evaluation of enrolled pats.) Less <<	September 30, 2019	-
NCT00408005	T Acute Lymphoblastic Leukemia... More >> T Lymphoblastic Lymphoma Less <<	Phase 3	Completed	-	-
NCT01959672	Pancreatic Adenocarcinoma ... More >> Resectable Pancreatic Carcinoma Stage I Pancreatic Cancer Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage II Pancreatic Cancer Stage IIA Pancreatic Cancer Stage IIB Pancreatic Cancer Stage III Pancreatic Cancer Less <<	Phase 2	Active, not recruiting	December 2019	United States, Nebraska ... More >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT02997228	Colorectal Adenocarcinoma ... More >> Mismatch Repair Deficiency Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less <<	Phase 3	Recruiting	April 30, 2022	-
NCT02896907	Pancreatic Adenocarcinoma ... More >> Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unresectable Pancreatic Carcinoma Less <<	Early Phase 1	Active, not recruiting	January 1, 2019	United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT02620865	Metastatic Pancreatic Adenocar... More >>cinoma Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Less <<	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Michigan ... More >> Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Less <<
NCT01307956	Adenocarcinoma of the Gastroes... More >>ophageal Junction Esophageal Adenocarcinoma Stage IIA Esophageal Cancer Stage IIB Esophageal Cancer Less <<	Phase 2	Terminated(Drug manufacturer -... More >> Amgen requested, per DSMB observation in POWER trial.) Less <<	-	United States, Nebraska ... More >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less <<
NCT01897454	Pancreatic Adenocarcinoma ... More >> Stage IIA Pancreatic Cancer Stage IIB Pancreatic Cancer Stage III Pancreatic Cancer Less <<	Phase 2	Unknown	-	United States, New York ... More >> Montefiore Medical Center-Weiler Hospital Recruiting Bronx, New York, United States, 10461 Contact: Jennifer W. Chuy 718-405-8404 JCHUY@montefiore.org Principal Investigator: Jennifer W. Chuy Less <<
NCT03300609	Colorectal Adenocarcinoma ... More >> RAS Wild Type Stage III Colorectal Cancer AJCC v7 Stage IIIA Colorectal Cancer AJCC v7 Stage IIIB Colorectal Cancer AJCC v7 Stage IIIC Colorectal Cancer AJCC v7 Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less <<	Phase 3	Recruiting	February 27, 2023	United States, California ... More >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Dana Agafitei 323-865-0467 Raluca.Agafitei@med.usc.edu Less <<
NCT01307956	-		Terminated(Drug manufacturer -... More >> Amgen requested, per DSMB observation in POWER trial.) Less <<	-	-
NCT02890355	Metastatic Pancreatic Adenocar... More >>cinoma Recurrent Pancreatic Carcinoma Stage IV Pancreatic Cancer AJCC v6 and v7 Less <<	Phase 2	Active, not recruiting	-	-
NCT02912559	Colon Adenocarcinoma ... More >> DNA Repair Disorder Lynch Syndrome Stage III Colon Cancer AJCC v7 Stage IIIA Colon Cancer AJCC v7 Stage IIIB Colon Cancer AJCC v7 Stage IIIC Colon Cancer AJCC v7 Less <<	Phase 3	Recruiting	July 1, 2020	-
NCT02042443	-		Completed	-	-
NCT02042443	Adult Cholangiocarcinoma ... More >> Advanced Adult Hepatocellular Carcinoma BCLC Stage C Adult Hepatocellular Carcinoma BCLC Stage D Adult Hepatocellular Carcinoma Hilar Cholangiocarcinoma Localized Non-Resectable Adult Liver Carcinoma Recurrent Adult Liver Carcinoma Recurrent Childhood Liver Cancer Recurrent Extrahepatic Bile Duct Carcinoma Recurrent Gallbladder Carcinoma Stage II Gallbladder Cancer Stage III Childhood Hepatocellular Carcinoma Stage IIIA Gallbladder Cancer Stage IIIB Gallbladder Cancer Stage IV Childhood Hepatocellular Carcinoma Stage IV Distal Bile Duct Cancer Stage IVA Gallbladder Cancer Stage IVB Gallbladder Cancer Unresectable Extrahepatic Bile Duct Carcinoma Less <<	Phase 2	Completed	-	-
NCT02508077	Recurrent Colorectal Carcinoma... More >> Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer Less <<	Phase 2	Terminated(Poor Accrual)	-	United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 City of Hope Antelope Valley Lancaster, California, United States, 93534 City of Hope Rancho Cucamonga Rancho Cucamonga, California, United States, 91730 South Pasadena Cancer Center South Pasadena, California, United States, 91030 Less <<
NCT02319018	Malignant Digestive System Neo... More >>plasm Less <<	Phase 1	Completed	-	United States, Connecticut ... More >> Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 Yale University New Haven, Connecticut, United States, 06520 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT01383343	Recurrent Colon Carcinoma ... More >> Recurrent Rectal Carcinoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Less <<	Phase 1	Completed	-	United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00957905	Recurrent Extragonadal Seminom... More >>a Recurrent Malignant Extragonadal Germ Cell Tumor Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor Recurrent Malignant Testicular Germ Cell Tumor Recurrent Ovarian Germ Cell Tumor Stage III Testicular Cancer Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor Stage IV Extragonadal Seminoma Stage IV Ovarian Germ Cell Tumor Less <<	Phase 2	Completed	-	United States, California ... More >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania UPMC-Presbyterian Hospital Pittsburgh, Pennsylvania, United States, 15213 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin Riverview Hospital Wisconsin Rapids, Wisconsin, United States, 54494 Less <<
NCT02508077	-		Terminated(Poor Accrual)	-	-
NCT03337087	Biliary System Disorder ... More >> BRCA1 Gene Mutation BRCA2 Gene Mutation Gastroesophageal Junction Adenocarcinoma Homologous Recombination Deficiency Metastatic Pancreatic Adenocarcinoma PALB2 Gene Mutation Stage IV Colorectal Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7 Less <<	Phase 1 Phase 2	Not yet recruiting	December 31, 2022	United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trial Referral Office 855-776-0015 Principal Investigator: Tanios S. Bekaii-Saab United States, Georgia Emory University Hospital/Winship Cancer Institute Not yet recruiting Atlanta, Georgia, United States, 30322 Contact: Christina S. Wu 404-778-0202 christina.wu@emoryhealthcare.org Principal Investigator: Christina S. Wu United States, Minnesota Mayo Clinic Not yet recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Wen Wee MA United States, Utah Huntsman Cancer Institute/University of Utah Not yet recruiting Salt Lake City, Utah, United States, 84112 Contact: Susan Sharry 801-585-3453 susan.sharry@hci.utah.edu Principal Investigator: Ignacio Garrido-Laguna Less <<
NCT00217737	Colon Mucinous Adenocarcinoma ... More >> Colon Signet Ring Cell Adenocarcinoma Lynch Syndrome Stage IIA Colon Cancer AJCC v7 Stage IIB Colon Cancer AJCC v7 Stage IIC Colon Cancer AJCC v7 Less <<	Phase 3	Active, not recruiting	-	-
NCT00957905	-		Completed	-	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 6035-45-6

{[proInfo.proName]}

CAS No.: 6035-45-6

Alternative Products

Product Details of Folinic acid calcium salt pentahydrate

Safety of Folinic acid calcium salt pentahydrate

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator